Misuse of Drugs (Miscellaneous Amendments) (No. 2) (Jersey) Order 2012


Misuse of Drugs (Miscellaneous Amendments) (No. 2) (Jersey) Order 2012

Made                                                                   14th September 2012

Coming into force                                                21st September 2012

THE MINISTER FOR HEALTH AND SOCIAL SERVICES, in pursuance of Articles 3, 4, 5, 8, 12, 13 and 27 of the Misuse of Drugs (Jersey) Law 1978[1], and after consultation with the Advisory Council on the Misuse of Drugs, orders as follows –

1        Schedule 2 to the Misuse of Drugs (Jersey) Law 1978 amended

(1)     In this Article “Law” means the Misuse of Drugs (Jersey) Law 1978[2].

(2)     In Part 1 of Schedule 2 to the Law, in paragraph 1(a), after the entry “Sufentanil” there shall be inserted the following entry –

“Tapentadol”.

(3)     In Part 2 of Schedule 2 to the Law –

(a)     in paragraph 1(a) after the entry “Methylphenobarbitone” there shall be inserted the entry –

“Nabilone”;

(b)     for the full stop at the end of paragraph 1(i) there shall be substituted a semi-colon; and

(c)     after paragraph 1(i) there shall be added the following sub-paragraphs –

“(j)     the following substances –

6-(2-aminopropyl)benzofuran

5-(2-aminopropyl)benzofuran;

(k)     Any compound (not being pipradrol) structurally derived from piperidine, pyrrolidine, azepane, morpholine or pyridine by substitution at a ring carbon atom with a diphenylmethyl group, whether or not the compound is further modified in any of the following ways, that is to say –

(i)      by substitution in any of the phenyl rings to any extent with alkyl, alkoxy, haloalkyl or halide groups,

(ii)      by substitution at the methyl carbon atom with an alkyl, hydroxyalkyl or hydroxy group,

(iii)     by substitution at the ring nitrogen atom with an alkyl, alkenyl, haloalkyl or hydroxyalkyl group.”.

(4)     For Part 3 of Schedule 2 to the Law there shall be substituted the following Part –

1.       The following substances, namely –

(a)     Alprazolam

Amineptine

Aminorex

Benzphetamine

Bromazepam

7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one;

Brotizolam

Buprenorphine

1-4 butanediol

Camazepam

Cathine

Cathinone

Chlordiazepoxide

Chlorphentermine

Clobazam

Clonazepam

Clorazepic acid

Clotiazepam

Cloxazolam

Delorazepam

Dextropropoxyphene

Diazepam

Diethylpropion

Estazolam

Ethchlorvynol

Ethinamate

Ethyl loflazepate

Fencamfamin

Fenethylline

Fenproporex

Fludiazepam

Flunitrazepam

Flurazepam

Gamma-butyrolactone;

Halazepam

Haloxazolam

4-hydroxybutanoic acid (4-hydroxy-n-butyric acid; gamma-hydroxybutyric acid)

Ketamine

Ketazolam

Loprazolam

Lorazepam

Lormetazepam

Mazindol

Medazepam

Mefenorex

Mephentermine

Meprobamate

Mesocarb

Methyprylone

Midazolam

Nimetazepam

Nitrazepam

Nordazepam

Oripavine

Oxazepam

Oxazolam

Pemoline

Phendimetrazine

Phentermine

Pinazepam

Prazepam

Propylhexedrine

Pyrovalerone

Temazepam

Tetrazepam

Triazolam

Zolpidem

N-Ethylamphetamine;

(b)     1-benzylpiperazine;

(c)     any compound structurally derived from 1-benzylpiperazine or 1-phenylpiperazine by modification in either of the following ways –

(i)      by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl substituents,

(ii)      by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide or haloalkyl substituents.

2.       The following substances –

Androst-4-ene-3, 17-diol

5α-Androstane-3, 17-diol

4-Androstene-3, 17-dione

5-Androstene-3, 17-diol

1-Androstenediol

1-Androstenedione

5-Androstenedione

Atamestane

Bolandiol

Bolasterone

Bolazine

Boldenone

Boldione

Bolenol

Bolmantalate

1,4-butanediol

Calusterone

4-Chloromethandienone

Clostebol

Danazol

Desoxymethyltestosterone

Drostanolone

Enestebol

Epitiostanol

Ethyloestrenol

Fluoxymesterone

Formebolone

Furazabol

Gestrinone

3-Hydroxy-5α-androstan-17-one

Mebolazine

Mepitiostane

Mesbolone

Mestanolone

Mesterolone

Methandienone

Methandriol

Methenolone

Methyltestosterone

Metribolone

Mibolerone

Nandrolone

19-Nor-4-Androstene-3, 17-dione

19-Nor-5-Androstene-3, 17-diol.

19-Norandrostenedione

19-Norandrosterone

Norboletone

Norclostebol

Norethandrolone

19-Noretiocholanolone

Ovandrotone

Oxabolone

Oxandrolone

Oxymesterone

Oxymetholone

Pipradrol

Prasterone

Prostanozol

Propetandrol

Quinbolone

Roxibolone

Silandrone

Stanolone

Stanozolol

Stenbolone

Testosterone

Tetrahydrogestrinone

Thiomesterone

Trenbolone.

3.       Any compound (not being Trilostane or a compound for the time being specified in paragraph 2) structurally derived from 17 hydroxyandrostan-3-one or from 17-hydroxy-estran-3-one by modification in any of the following ways –

(a)     by further substitution at position 17 by a methyl or ethyl group;

(b)     by substitution to any extent at one or more positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;

(c)     by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than 2 ethylenic bonds in any one carbocyclic ring;

(d)     by fusion of ring A with a heterocyclic system.

4.       Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 2 or described in paragraph 3.

5.       Chorionic Gonadotrophin (HCG)

Non-human chorionic gonadotrophin

Somatotropin

Somatrem

Somatropin

Zeranol

Zilpaterol.

6.       Clenbuterol.

7.       Any stereoisomeric form of a substance for the time being specified in any of paragraphs 1 to 6 of this Part not being phenylpropanolamine.

8.       Any salt of a substance for the time being specified in any of paragraphs 1 to 7 of this Part.

9.       Any preparation or other product containing a substance for the time being specified in any of paragraphs 1 to 8 of this Part.

10.     The following substances –

(a)     2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone;

(b)     any stereoisomeric form of 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone;

(c)     any ester or ether of a substance specified in sub-paragraph (a) or (b);

(d)     any salt of a substance specified in any of sub-paragraphs (a) to (c); and

(e)     any preparation or other product containing a substance specified in any of sub-paragraphs (a) to (d).”.

2        Schedule to the Misuse of Drugs (Designation) (Jersey) Order 1989 amended

In Part 1 of the Schedule to the Misuse of Drugs (Designation) (Jersey) Order 1989[3] –

(a)     for paragraph 1(a) there shall be substituted the following sub-paragraph –

“(a)    1,4-butanediol

1-(3,4-Methylenedioxybenzyl)butyl-(ethyl)amine

1-(3,4-Methylenedioxybenzyl)butyl-(methyl)amine

2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine

2-(1,4-Dimethoxy-2-naphthyl)ethylamine

2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine

2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine

2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine

2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine

2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine

2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine

2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine

2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine

2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine

2-(α-Methyl-3,4-methylenedioxyphenethylamino)ethanol

2,5-Dimethoxy-α, 4-dimethyl-phenethylamine

2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol

2-Amino-1-(3,4-dimethoxyphenyl)ethanol

2-Methoxyethyl(α-methyl-3,4-methylenedioxyphenethyl)amine

4-Bromo- β,2,5-trimethoxyphenethylamine

4-Bromo-2, 5-dimethoxy- methyl-phenethylamine

4-Iodo-2,5-dimethoxy-α-methylphenethyl(dimethyl)amine

4-Methyl-aminorex

Allyl(α-methyl-3,4-methylenedioxyphenethyl)amine

Amphetamine

Benzyl(α-methyl-3,4-methylenedioxyphenethyl)amine

Bufotenine

Cannabinol

Cannabinol derivatives except dronabinol and except any sterioisomer of dronabinol

Cannabis

Cannabis resin

Cathinone

Coca leaf

Concentrate of poppy-straw

Cyclopropylmethyl(α-methyl-3,4-methylenedioxyphenethyl)amine

Dihydroetorphine

Dimethyl(α-methyl-3,4-methylenedioxyphenethyl)amine

Eticyclidine

Etryptamine

Gamma-butyrolactone

4-hydroxybutanoic acid (4-hydroxy-n-butyric acid; gamma-hydroxybutyric acid)

Lysergamide

Lysergide and other N-alkyl derivatives of lysergamide

Mescaline

Methcathinone

Methylamphetamine

N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxyl-amine

N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxyl-amine

N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxyl-amine

N.N-Diethyltryptamine

N.N-Dimethyltryptamine

N-Hydroxy-tenamphetamine

N-Methyl-N-(α-methyl-3,4-methylenedioxyphenethyl)hydro-xylamine

O-Methyl-N-(α-methyl-3,4-methylenedioxyphenethyl)hydro-xylamine

Psilocin

Raw opium

Rolicyclidine

Tenocyclidine

α, α-Dimethyl-3,4-methylenedioxyphenethyl (methyl)amine

α, α-Dimethyl-3,4-methylenedioxyphenethylamine

α-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine

α-Methyl-4-(methylthio)phenethylamine (also known as 4-Methylthioamphetamine)

α-Methylphenethylhydroxylamine (also known as N-Hydroxyamphetamine)

β -Methoxy-3,4-methylenedioxyphenethylamine

β,2,5-Trimethoxy-4-methylphenethylamine

β,3,4,5-Tetramethoxyphenethylamine;”;

(b)     in paragraph 1(n) for the full stop there shall be substituted a semi-colon; and

(c)     after paragraph 1(n) there shall be added the following sub-paragraph –

“(o)    Any compound (not being pipradrol) structurally derived from piperidine, pyrrolidine, azepane, morpholine or pyridine by substitution at a ring carbon atom with a diphenylmethyl group, whether or not the compound is further modified in any of the following ways, that is to say –

(i)      by substitution in any of the phenyl rings to any extent with alkyl, alkoxy, haloalkyl or halide groups,

(ii)      by substitution at the methyl carbon atom with an alkyl, hydroxyalkyl or hydroxy group,

(iii)     by substitution at the ring nitrogen atom with an alkyl, alkenyl, haloalkyl or hydroxyalkyl group.”.

3        Misuse of Drugs (General Provisions) (Jersey) Order 2009 amended

(1)     In this Article “Order” means the Misuse of Drugs (General Provisions) (Jersey) Order 2009[4].

(2)     In Article 1, after the definition “Schedule 5 drug” there shall be inserted the following definition –

“ ‘Schedule 6 drug’ means a controlled drug specified in Schedule 6;”.

(3)     For Article 2 there shall be substituted the following Article –

“2      Exemptions from certain provisions of Law

(1)     Articles 4(1) (importation and exportation) and 8(1) (possession) of the Law do not have effect in respect of a Schedule 5 drug.

(2)     Articles 5 (production and supply) and 8(1) of the Law do not have effect in respect of poppy-straw.

(3)     Articles 4(1), 5 and 8(1) of the Law do not have effect in respect of exempt products.

(4)     Articles 4(1), 5 and 8(1) of the Law do not have effect in respect of a Schedule 6 drug except in any case where the importation, exportation, production, supply, offer to supply or possession of the drug is by a person knowing or believing that the drug will be used for the purpose of human ingestion other than as a flavouring in food, whether by that person or another person.”.

(4)     In Schedule 1 to the Order –

(a)     in paragraph 1(a) the entry “Gammahydroxybutyrate” shall be omitted;

(b)     for the full stop at the end of paragraph 1(r) there shall be substituted a semi-colon; and

(c)     after paragraph 1(r) there shall be added the following paragraphs –

“(s)    Any compound (not being pipradrol) structurally derived from piperidine, pyrrolidine, azepane, morpholine or pyridine by substitution at a ring carbon atom with a diphenylmethyl group, whether or not the compound is further modified in any of the following ways, that is to say –

(i)      by substitution in any of the phenyl rings to any extent with alkyl, alkoxy, haloalkyl or halide groups,

(ii)      by substitution at the methyl carbon atom with an alkyl, hydroxyalkyl or hydroxy group,

(iii)     by substitution at the ring nitrogen atom with an alkyl, alkenyl, haloalkyl or hydroxyalkyl group;

(t)      6-(2-aminopropyl)benzofuran

5-(2-aminopropyl)benzofuran.”;

(d)     after paragraph 5 there shall be added the following paragraph –

“6      The following substances and products –

(a)     2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone;

(b)     any stereoisomeric form of 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone;

(c)     any ester or ether of a substance specified in sub-paragraph (a) or (b);

(d)     any salt of a substance specified in any of sub-paragraphs (a) to (c); and

(e)     any preparation or other product containing a substance specified in any of sub-paragraphs (a) to (d).”.

(5)     In Schedule 2 to the Order, in paragraph 1 –

(a)     after the entry “Alphaprodine” there shall be inserted the following entry –

“Amineptine”;

(b)     after the entry “Myrophine” there shall be inserted the following entry –

“Nabilone”;

(c)     after the entry “Norpipanone” there shall be inserted the following entry –

“Oripavine”;

(d)     after the entry “Sufentanil” there shall be inserted the following entry –

“Tapentadol”.

(6)     for Schedule 3 to the Order there shall be substituted the following Schedule –

1        The following substances, namely –

(a)     Benzphetamine

7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one

Cathine

Chlorphentermine

Ethchlorvynol

Ethinamate

Flunitrazepam

Mazindol

Mephentermine

Meprobamate

Methylphenobarbitone

Methyprylone

Phendimetrazine

Pipradrol

Temazepam

(b)     any 5,5 disubstituted barbituric acid not being quinalbarbitone.

2        Any ester or ether of pipradrol.

3        Any stereoisomeric form of a substance specified in paragraph 1 or 2 not being phenylpropanolamine.

4        Any salt of a substance specified in any of paragraphs 1 to 3.

5        Any preparation or other product containing a substance specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.”.

(7)     For Schedule 4 to the Order there shall be substituted the following Schedule –

1        The following substances and products –

Alprazolam

Aminorex

Bromazepam

Brotizolam

Camazepam

Chlordiazepoxide

Clobazam

Clonazepam

Clorazepic acid

Clotiazepam

Cloxazolam

Delorazepam

Diazepam

Estazolam

Ethyl loflazepate

Fencamfamin

Fenproporex

Fludiazepam

Flurazepam

Halazepam

Haloxazolam

4-hydroxybutanoic acid (4-hydroxy-n-butyric acid; gamma-hydroxybutyric acid)

Ketamine

Ketazolam

Loprazolam

Lorazepam

Lormetazepam

Medazepam

Mefenorex

Mesocarb

Midazolam

Nimetazepam

Nitrazepam

Nordazepam

Oxazepam

Oxazolam

Pemoline

Pinazepam

Prazepam

Propylhexedrine

Pyrovalerone

Tetrazepam

Triazolam

Zolpidem

N-Ethylamphetamine.

2        The following substances –

5α-Androstane-3, 17-diol

4-Androstene-3, 17-dione

5-Androstene-3, 17-diol

Androst-4-ene-3, 17-diol

1-Androstenediol

1-Androstenedione

5-Androstenedione

Atamestane

Bolandiol

Bolasterone

Bolazine

Boldenone

Boldione

Bolenol

Bolmantalate

Calusterone

4-Chloromethandienone

Clostebol

Danazol

Desoxymethyltestosterone

Drostanolone

Enestebol

Epitiostanol

Ethyloestrenol

Fluoxymesterone

Formebolone

Furazabol

Gestrinone

3-Hydroxy-5α-androstan-17-one

Mebolazine

Mepitiostane

Mesbolone

Mestanolone

Mesterolone

Methandienone

Methandriol

Methenolone

Methyltestosterone

Metribolone

Mibolerone

Nandrolone

19-Nor-4-Androstene-3, 17-dione

19-Nor-5- Androstene-3, 17-diol

19-Norandrostenedione

19-Norandrosterone

19-Noretiocholanolone

Norboletone

Norclostebol

Norethandrolone

Ovandrotone

Oxabolone

Oxandrolone

Oxymesterone

Oxymetholone

Prasterone

Propetandrol

Prostanozol

Quinbolone

Roxibolone

Silandrone

Stanolone

Stanozolol

Stenbolone

Tetrahydrogestrinone

Testosterone

Thiomesterone

Trenbolone.

3        Any compound (not being Trilostane or a compound specified in paragraph 2) structurally derived from 17 hydroxyandrostan-3-one or from 17-hydroxy-estran-3-one by modification –

(a)     by further substitution at position 17 by a methyl or ethyl group;

(b)     by substitution to any extent at one or more positions 1, 2, 4, 6, 7, 9, 11, or 16, but at no other position;

(c)     by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than 2 ethylenic bonds in any one carbocyclic ring; or

(d)     by fusion of ring A with a heterocyclic system.

4        Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 2 or paragraph 3.

5        Chorionic Gonadotrophin (HCG)

Non-human chorionic gonadotrophin

Somatotropin

Somatrem

Somatropin

Zeranol

Zilpaterol.

6        Clenbuterol.

7        Any stereoisomeric form of a substance specified in any of paragraphs 1 to 6.

8        Any salt of a substance specified in any of paragraphs 1 to 7.

9        Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 8 not being a preparation specified in Schedule 5.”.

(8)     After Schedule 5 there shall be added the following Schedule –

“SCHEDULE 6

(Article 2(4))

SCHEDULE 6 DRUGS

1        Gamma–butyrolactone including –

(a)     any salt of gamma–butyrolactone; and

(b)     any preparation or other product containing gamma–butyrolactone or a substance specified in sub-paragraph (a).

2        1,4–butanediol including –

(a)     any substance which is an ester or ether or both an ester and ether of 1,4‑butanediol;

(b)     any salt of 1,4–butanediol or of a substance specified in sub-paragraph (a); and

(c)     any preparation or other product containing 1,4–butanediol or a substance specified in sub-paragraph (a) or (b).”.

4        Citation and commencement

This Order shall be cited as the Misuse of Drugs (Miscellaneous Amendments) (No. 2) (Jersey) Order 2012 and shall come into force 7 days after it is made.

deputy a.e. pryke of trinity

Minister for Health and Social Services

 


 



[1]                                    chapter 08.680

[2]                                    chapter 08.680

[3]                                    chapter 08.680.40

[4]                                    chapter 08.680.60


Page Last Updated: 16 Jun 2015